Detail akcie Nutra Pharma online

Business Summary: Nutra Pharma Corporation operates as a biotechnology company specializing in the acquisition, licensing, and commercialization of pharmaceutical products and technologies for the management of neurological disorders, cancer, autoimmune, and infectious diseases, including Multiple Sclerosis (MS), Human Immunodeficiency Virus (HIV), Adrenomyeloneuropathy (AMN) and Pain. The Company's drug candidates include RPI-MN and RPI-78M. RPI-MN is used to treat neurological diseases and autoimmune diseases, including Multiple Sclerosis (MS), Adrenomyeloneuropathy (AMN), Amyotrophic Lateral Sclerosis (ALS or Lou Gehrig’s disease), Rheumatoid Arthritis (RA) and Myasthenia Gravis. The RPI-78M is used to treat viral diseases, including HIV/AIDS and Herpes. The Company offers Nyloxin/Nyloxin Extra Strength as its over-the-counter (OTC) pain reliever. It is focused upon marketing homeopathic drugs for the treatment of pain: Nyloxin, Nyloxin Extra Strength Pet Pain, Equine Pain, and Luxury Feet.
Financial Summary: BRIEF: For the nine months ended 30 September 2024, Nutra Pharma Corp. revenues decreased 41% to $271K. Net loss decreased 8% to $1.1M. Revenues reflect Net sales to a related party decrease of 65% to $106K. Lower net loss reflects Designer Diagnostic inc segment loss decrease of 6% to $700K.